A study to assess the effect of AZD5634 on mucociliary clearance, safety, tolerability and pharmacokinetic parameters in patients with cystic fibrosis

Trial Identifier: D6600C00002
Sponsor: AstraZeneca
Collaborator:
PAREXEL
NCTID:: NCT02950805
Start Date: May 2017
Primary Completion Date: April 2018
Study Completion Date: April 2018
Condition: Lungs & Respiratory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation

Trial Locations

Country Location
United States of America, AL Birmingham, AL, United States of America, 35294-1785
United States of America, MD Baltimore, MD, United States of America, 21205
United States of America, North Carolina Chapel Hill, North Carolina, United States of America, 27517